Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Zenas BioPharma (ZBIO) EBT Margin (2023 - 2025)

Zenas BioPharma has reported EBT Margin over the past 3 years, most recently at 337.78% for Q1 2025.

  • Quarterly results put EBT Margin at 337.78% for Q1 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was 106.93% (up 332527.0% YoY), and the annual figure for FY2025 was 106.93%, up 332529.0%.
  • EBT Margin for Q1 2025 was 337.78% at Zenas BioPharma, up from 1130.68% in the prior quarter.
  • Over the last five years, EBT Margin for ZBIO hit a ceiling of 71.25% in Q3 2023 and a floor of 1130.68% in Q4 2024.
  • Median EBT Margin over the past 3 years was 337.78% (2025), compared with a mean of 465.74%.